
Applied Therapeutics APLT
Quartalsbericht 2025-Q3
hinzugefügt 13.11.2025
Applied Therapeutics Zahlungsmittel 2011-2026 | APLT
Zahlungsmittel Jährlich Applied Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.9 M | 16.7 M | 53.9 M | 57.5 M | 18.8 M | 18.7 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 57.5 M | 16.7 M | 35.9 M |
Zahlungsmittel Vierteljährlich Applied Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.9 M | 30.4 M | 79.4 M | 98.9 M | 122 M | 49.9 M | 37.5 M | 35.6 M | 22.9 M | 16.7 M | 40.4 M | 55.7 M | 38.2 M | 53.9 M | 70.2 M | 78.4 M | 84.1 M | 57.5 M | 57.5 M | 57.5 M | 57.5 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 3.28 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 122 M | 3.28 M | 43.7 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
616 M | $ 219.68 | 1.92 % | $ 5 B | ||
|
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | ||
|
Seres Therapeutics
MCRB
|
128 M | $ 8.28 | - | $ 1.06 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 19.45 | 1.14 % | $ 909 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | ||
|
Mesoblast Limited
MESO
|
60.4 M | $ 15.44 | 7.82 % | $ 10 B | ||
|
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
3.33 M | $ 0.67 | -5.25 % | $ 7.67 M | ||
|
Mirum Pharmaceuticals
MIRM
|
297 M | $ 90.39 | 2.86 % | $ 4.54 B | ||
|
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.34 | 1.52 % | $ 342 M | ||
|
MediciNova
MNOV
|
30.8 M | $ 1.45 | - | $ 71.1 M | ||
|
CytomX Therapeutics
CTMX
|
12.7 M | $ 4.37 | 2.95 % | $ 603 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
3.14 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
31 M | $ 2.69 | 1.37 % | $ 16.9 M | ||
|
Dynavax Technologies Corporation
DVAX
|
95.9 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
92.7 K | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
Merck & Co.
MRK
|
14.6 B | $ 117.56 | 1.02 % | $ 294 B | ||
|
Marker Therapeutics
MRKR
|
16.1 M | $ 1.37 | 8.73 % | $ 21 M | ||
|
Moderna
MRNA
|
2.6 B | $ 53.09 | 3.41 % | $ 20.7 B | ||
|
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.47 | 3.71 % | $ 856 M | ||
|
Homology Medicines
FIXX
|
48.3 M | - | 0.77 % | $ 53.4 M |